Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery.
Majowicz A, Maczuga P, Kwikkers KL, van der Marel S, van Logtenstein R, Petry H, van Deventer SJ, Konstantinova P, Ferreira V. Majowicz A, et al. Among authors: van der marel s, van deventer sj, van logtenstein r. J Gene Med. 2013 Jun-Jul;15(6-7):219-32. doi: 10.1002/jgm.2712. J Gene Med. 2013. PMID: 23658149
Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis.
van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, Meijer SL, van Deventer SJ, Petry H, Hommes DW, Ferreira V. van der Marel S, et al. Among authors: van deventer sj, van logtenstein r. World J Gastroenterol. 2012 Aug 28;18(32):4288-99. doi: 10.3748/wjg.v18.i32.4288. World J Gastroenterol. 2012. PMID: 22969191 Free PMC article.
Gene and cell therapy based treatment strategies for inflammatory bowel diseases.
van der Marel S, Majowicz A, van Deventer S, Petry H, Hommes DW, Ferreira V. van der Marel S, et al. Among authors: van deventer s. World J Gastrointest Pathophysiol. 2011 Dec 15;2(6):114-22. doi: 10.4291/wjgp.v2.i6.114. World J Gastrointest Pathophysiol. 2011. PMID: 22180846 Free PMC article.
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP, Mingozzi F, van der Marel S, Su Y, Garman R, Ferreira V, Martin W, Scott DW, De Groot AS. Cousens LP, et al. Among authors: van der marel s. Hum Vaccin Immunother. 2012 Oct;8(10):1459-64. doi: 10.4161/hv.21405. Epub 2012 Oct 1. Hum Vaccin Immunother. 2012. PMID: 23095864 Free PMC article.
Quality of web-based information on inflammatory bowel diseases.
van der Marel S, Duijvestein M, Hardwick JC, van den Brink GR, Veenendaal R, Hommes DW, Fidder HH. van der Marel S, et al. Among authors: van den brink gr. Inflamm Bowel Dis. 2009 Dec;15(12):1891-6. doi: 10.1002/ibd.20976. Epub 2009 May 21. Inflamm Bowel Dis. 2009. PMID: 19462423
Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D Haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis. Volkers A, et al. Among authors: van der marel s. Aliment Pharmacol Ther. 2022 Sep;56(6):1044-1054. doi: 10.1111/apt.17153. Epub 2022 Jul 23. Aliment Pharmacol Ther. 2022. PMID: 35869807 Free PMC article.
Disease activity in inflammatory bowel disease patients is associated with increased liver fat content and liver fibrosis during follow-up.
van Lingen E, Tushuizen ME, Steenhuis MEJ, van Deynen T, Martens J, Morales DD, van der Meulen-de Jong AE, Molendijk I, van der Marel S, Maljaars PWJ. van Lingen E, et al. Among authors: van der marel s, van deynen t, van der meulen de jong ae. Int J Colorectal Dis. 2022 Feb;37(2):349-356. doi: 10.1007/s00384-021-04065-8. Epub 2021 Nov 17. Int J Colorectal Dis. 2022. PMID: 34791524
Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, Löwenberg M, van der Marel S, de Boer NKH, Bodelier AGL, Jansen JM, West RL, Haans JJL, van Dop WA, Weersma RK, Hoentjen F, Maljaars PWJ; Dutch Initiative on Crohn and Colitis (ICC). Asscher VER, et al. Among authors: van der marel s, van dop wa. Aliment Pharmacol Ther. 2020 Oct;52(8):1366-1376. doi: 10.1111/apt.16073. Epub 2020 Sep 9. Aliment Pharmacol Ther. 2020. PMID: 32901983 Free PMC article.
31 results